NANTES, France – June 2, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided clinical updates on Tedopi®, the “off-the-shelf” neo-epitope-based ...

French biotech OSE Immunotherapeutics is taking charge of a new project aimed at fast-tracking nanodrug development and creating new mRNA therapeutics, with 1.3 million euros ($1.47 million ...

Mowi has today signed a EUR 2,600 million five-year sustainability-linked multicurrency revolving credit facility agreement with DNB, Nordea, Rabobank, ABN AMRO, Danske Bank, SEB and Crédit Agricole.

Nantes, June 9th, 2025, 8 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) informs its shareholders and the market of the update on the terms of the Combined General Meeting scheduled ...

Mowi has today signed a EUR 2,600 million five-year sustainability-linked multicurrency revolving credit facility agreement with DNB, Nordea, Rabobank, ABN AMRO, Danske Bank, SEB and Crédit Agricole.

Kwa-Thema – Sparrows came out victorious over XI Experience in the battle of the U11s at Kwa-Thema Sports Complex on Saturday. Although the boys in red (XI Experience) stepped onto the lawn with ...

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Immunotherapeutics.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Hey, let’s fire the hitting coach! The Texas Rangers, before dismissing Donnie Ecker on May 4 and replacing him with Bret Boone, were 17-18 and averaging 3.23 runs per game. Since the arrival of ...

KATHRYN Thomas has backed her co-host to replace RTE's icon Joe Duffy on Liveline. Speculation over who will be replacing the radio veteran has been rife since revealing he's leaving his hugely ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...